Dynamics of IDH1 Mutation and Protein Expression Between Primary and Recurrent Gliomas and Their Prognostic Significance.
- 1Department of Radiation Oncology Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China zju.edu.cn.
- 2Cancer Institute (Key Laboratory of Cancer Prevention and Intervention National Ministry of Education) Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China zju.edu.cn.
- 3Zhejiang Chinese Medical University Hangzhou China zcmu.edu.cn.
Abstract
Background
Isocitrate dehydrogenase 1 (IDH1) mutation is a key molecular marker in gliomas and is generally associated with favorable prognosis. However, its dynamic changes and prognostic significance during tumor recurrence remain incompletely understood.Methods
We conducted a retrospective analysis of 42 patients with paired primary and recurrent glioma samples. IDH1 mutation status was determined by PCR, and the expression of IDH1 R132H protein was evaluated using a semiquantitative scoring system ranging from negative (-) to strongly positive (+++) based on expression intensity by immunohistochemistry (IHC). Changes in molecular features and WHO grade were analyzed, and their associations with progression-free survival (PFS), overall survival (OS), and postrecurrence survival (PRS) were evaluated using Cox regression models.Results
IDH1 mutation status remained largely stable between primary and recurrent tumors, with most patients retaining their original genotype. In contrast, WHO grade progression was observed in 45.2% of cases, indicating ongoing tumor evolution. IDH1 R132H protein expression exhibited dynamic changes, with both upregulation and downregulation detected at recurrence. In primary tumors, IDH1 mutation was independently associated with improved PFS (HR = 0.351, p = 0.016), whereas higher IDH1 R132H expression was associated with improved OS (HR = 0.371, p = 0.032). In recurrent tumors, IDH1 mutation showed a trend toward inferior PRS, although this association did not reach statistical significance, suggesting that the prognostic relevance of IDH1 alterations may vary during glioma evolution.Conclusions
Although IDH1 mutation remains largely stable during glioma progression, its prognostic associations may vary between primary and recurrent disease. IDH1 R132H protein expression also shows dynamic changes and may provide complementary prognostic information. These exploratory findings support integrating genetic and protein-level biomarkers when evaluating glioma progression and warrant validation before informing the clinical application of IDH inhibitors.
Related
- Prognostic Significance of p53 Immunohistochemical Expression and Molecular Characterization of TP53 Variants in Triple-Negative Breast Cancer After Neoadjuvant Chemotherapy
- Prognostic Significance of B7-H3, TROP2, and p16 Expression in Pleural Mesothelioma: Clinicopathological Correlations and Survival Outcomes
- Prognostic significance of EGFR-1 and VEGF-A expression in feline cutaneous squamous cell carcinoma.
- Prognostic significance of CK7, CK20, and CDX2 expression in small intestinal adenocarcinoma.
- ORC1 expression features and its prognostic significance in HBV-associated hepatocellular carcinoma
BibTeX
@article{yu2026dynamics,
title = {{Dynamics of IDH1 Mutation and Protein Expression Between Primary and Recurrent Gliomas and Their Prognostic Significance.}},
author = {Wei Yu and Siyu Guo and Beibei Liu and Qichun Wei},
journal = {Human mutation},
year = {2026},
month = oct,
doi = {10.1155/humu/7543241},
url = {https://europepmc.org/article/MED/42948477},
note = {CC BY},
}
RIS
TY - JOUR
TI - Dynamics of IDH1 Mutation and Protein Expression Between Primary and Recurrent Gliomas and Their Prognostic Significance.
AU - Wei Yu
AU - Siyu Guo
AU - Beibei Liu
AU - Qichun Wei
PY - 2026
DA - 2026/10/27
JO - Human mutation
DO - 10.1155/humu/7543241
UR - https://europepmc.org/article/MED/42948477
AB - Background Isocitrate dehydrogenase 1 (IDH1) mutation is a key molecular marker in gliomas and is generally associated with favorable prognosis. However, its dynamic changes and prognostic significance during tumor recurrence remain incompletely understood.Methods We conducted a retrospective analysis of 42 patients with paired primary and recurrent glioma samples. IDH1 mutation status was determined by PCR, and the expression of IDH1 R132H protein was evaluated using a semiquantitative scoring system ranging from negative (-) to strongly positive (+++) based on expression intensity by immunohistochemistry (IHC). Changes in molecular features and WHO grade were analyzed, and their associations with progression-free survival (PFS), overall survival (OS), and postrecurrence survival (PRS) were evaluated using Cox regression models.Results IDH1 mutation status remained largely stable between primary and recurrent tumors, with most patients retaining their original genotype. In contrast, WHO grade progression was observed in 45.2% of cases, indicating ongoing tumor evolution. IDH1 R132H protein expression exhibited dynamic changes, with both upregulation and downregulation detected at recurrence. In primary tumors, IDH1 mutation was independently associated with improved PFS (HR = 0.351, p = 0.016), whereas higher IDH1 R132H expression was associated with improved OS (HR = 0.371, p = 0.032). In recurrent tumors, IDH1 mutation showed a trend toward inferior PRS, although this association did not reach statistical significance, suggesting that the prognostic relevance of IDH1 alterations may vary during glioma evolution.Conclusions Although IDH1 mutation remains largely stable during glioma progression, its prognostic associations may vary between primary and recurrent disease. IDH1 R132H protein expression also shows dynamic changes and may provide complementary prognostic information. These exploratory findings support integrating genetic and protein-level biomarkers when evaluating glioma progression and warrant validation before informing the clinical application of IDH inhibitors.
SN - 1059-7794
SN - 1098-1004
ER -